TickerFacts.

SELLAS Life Sciences Group, Inc. (SLS): Cost of Revenue

Annual figures by period end, from SEC filings.

$0
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
$200.0K2020-12-31: $02021-12-31: $200.0K2022-12-31: $100.0K2023-12-31: $02024-12-31: $02025-12-31: $0$0
2020-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$0n/a2026-03-19, From 2025-01-01
2024-12-31$0n/a2026-03-19, From 2024-01-01
2023-12-31$0-100.0%2025-03-20, From 2023-01-01
2022-12-31$100.0K-50.0%2024-03-28, From 2022-01-01
2021-12-31$200.0Kn/a2023-03-16, From 2021-01-01
2020-12-31$0n/a2022-03-31, From 2020-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
SELLAS Life Sciences Group, Inc. (SLS)2025-12-31$0n/a
Cumberland Pharmaceuticals Inc (CPIX)2025-12-31$6.67M+1.2%
Scienture Holdings, Inc. (SCNX)2025-12-31$100.1K-23.4%
Pyxis Oncology, Inc. (PYXS)2025-12-31$2.39M+402.7%
Eton Pharmaceuticals, Inc. (ETON)2025-12-31$37.21M+138.5%
Journey Medical Corp (DERM)2025-12-31$20.92M+0.2%
Lifevantage Corp (LFVN)2026-06-30$40.97M-8.7%
ProPhase Labs, Inc. (PRPH)2025-12-31$2.96M-57.2%
Aytu Biopharma, Inc (AYTU)2026-06-30$20.75M+1.0%

Compare SLS, CPIX, SCNX, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗